Small Pharma To Announce Results of SPL026 Phase IIa Trial for...

Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial...

Panel: Three Psychedelics Companies that Raised in 2022

PT383 – Identity, Rage, Culture, and Venture Capital

Panel: Psychedelic VCs Reflect on 2022

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Psychedelic Funding in 2022

Rick Doblin – The Balance at MAPS Between Public Benefit and...

Expanding ketamine’s horizons for rare neurological disorders

Psychedelics in the Public Markets: 2022

Load more